迪哲医药：DZD8586获美国FDA快速通道认定

Core Viewpoint - DZD8586, a product under development by the company, has received "Fast Track Designation" from the US FDA for the treatment of relapsed refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two lines of therapy [1] Group 1 - The product DZD8586 is a globally innovative dual-target inhibitor of LYN/BTK, capable of blocking both BTK-dependent and independent BCR signaling pathways [1]